{u'keywords': [u'diastereomeric salt formation', u'Dr Watson', u'enantiomers', u'Professor', u'Professor Banwell', u'enantiomer', u'Professor Rae', u'Professor Jarrott', u'activity', u'platelet aggregation', u'compound', u'Mr Badorc', u'PCR', u'racemic mixture', u'patent', u'organic chemistry', u'common general knowledge', u'dextro-rotatory enantiomer', u'active enantiomer', u'asymmetric synthesis', u'prior art patents', u'compounds', u'Professor Easton', u'levo-rotatory enantiomer', u'dextro-rotatory isomer', u'racemic compound PCR', u'optically active enantiomers', u'university', u'single enantiomers', u'toxicity', u'optical rotatory power', u'aggregation inhibiting activity', u'individual enantiomers', u'pharmaceutically acceptable mineral', u'Monash University', u'biological activity', u'stereochemistry', u'Sanofi-Aventis', u'relation', u'salt formation technique', u'salt formation process', u'lower alkyl', u'French patent', u'priority date', u'camphor-10-sulfonic acid', u'separate enantiomers', u'French patent application', u'salts', u'pharmaceutically acceptable salt', u'platelet aggregation inhibitor'], u'casename': u'Apotex Pty Ltd (formerly GenRx Pty Ltd) v Sanofi-Aventis [2008] FCA 1194 (12 August 2008)', u'filename': u'training_data/08_1194.xml'}